Dr. Jeffrey Lieberman
Jeffrey A. Lieberman, M.D., one of the world’s foremost experts on schizophrenia and other severe psychiatric disorders, is chairman and professor of psychiatry at Columbia University in New York City. He also directs the New York State Psychiatric Institute and serves as psychiatrist-in-chief at Columbia University Medical Center.
His extensive research on schizophrenia has helped advance the understanding of the development and course of this disease, and the mechanisms and effectiveness of antipsychotic drugs for treating psychotic conditions. His work has been reported in more than 300 articles in the scientific literature, and he has edited or co-edited many books and professional journals.
Among many honors, Dr. Lieberman was elected to the National Academies' Institute of Medicine. He is a member of NARSAD's Scientific Council, has twice received NARSAD Distinguished Investigator grants and was awarded the organization's 2006 Lieber Prize for Outstanding Achievement in Schizophrenia Research.
Dr. Lieberman received his medical degree from the George Washington School of Medicine in 1975. Following his postgraduate training in psychiatry at St. Vincent’s Hospital and Medical Center of New York Medical College, he was on the faculties of the Albert Einstein College of Medicine and Mount Sinai School of Medicine, and served as Director of Research at the Hillside Hospital of Long Island Jewish Medical Center.
Prior to moving to Columbia he was the Vice Chairman for Research and Scientific Affairs in the Department of Psychiatry and Director of the Mental Health and Neuroscience Center at the University of North Carolina, School of Medicine in Chapel Hill.
Dr. Lieberman’s research has focused on the neurobiology, pharmacology and treatment of schizophrenia and related psychotic disorders. In this context, his work has advanced our understanding of the natural history and phenomenology of schizophrenia and its pathophysiological basis, and the mechanism of action and clinical effectiveness of antipsychotic drugs.